World Journal of Gastrointestinal Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2186676, encodeId=001a21866e6c9, content=有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884f5530521, createdName=ms2000001910337374, createdTime=Fri Feb 09 12:33:15 CST 2024, time=2024-02-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140483, encodeId=e6f4214048336, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;感染 经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a88208497, createdName=ms6000000805711537, createdTime=Fri Jun 02 15:03:18 CST 2023, time=2023-06-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2106507, encodeId=4183210650e75, content=有没有投过的老师分享一下经验呀，初审需要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b35703719, createdName=ms5000000599592392, createdTime=Sat Dec 17 21:00:16 CST 2022, time=2022-12-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1235822, encodeId=c65c123582270, content=偏重的研究方向：胃肠 经验分享：稿费多少钱啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193c8146336, createdName=ms7000000646981835, createdTime=Sun Jul 31 22:09:59 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191094, encodeId=fdbe119109436, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：食管癌;免疫组化 经验分享：请问这个杂志的WOS号多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c665384789, createdName=我恨梅斯Medsci, createdTime=Tue Feb 08 17:41:55 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589105, encodeId=e26a58910511, content=请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5afc5268272, createdName=14818c93m26暂无昵称, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580891, encodeId=9ceb580891c5, content=结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Tue Dec 03 00:00:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576697, encodeId=31975e669707, content=投了137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , beContent=137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575337, encodeId=8a9a5e533738, content=你投了？ ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表: 没有人投这个杂志吗？一点信息都没有, beContent=ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6aca5170385, createdName=146d61a5m67暂无昵称, createdTime=Mon Aug 26 00:00:00 CST 2019, time=2019-08-26, status=1, ipAttribution=)]

2024-02-09 ms2000001910337374 来自北京

有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志

19 0

[GetPortalCommentsPageByObjectIdResponse(id=2186676, encodeId=001a21866e6c9, content=有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884f5530521, createdName=ms2000001910337374, createdTime=Fri Feb 09 12:33:15 CST 2024, time=2024-02-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140483, encodeId=e6f4214048336, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;感染 经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a88208497, createdName=ms6000000805711537, createdTime=Fri Jun 02 15:03:18 CST 2023, time=2023-06-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2106507, encodeId=4183210650e75, content=有没有投过的老师分享一下经验呀，初审需要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b35703719, createdName=ms5000000599592392, createdTime=Sat Dec 17 21:00:16 CST 2022, time=2022-12-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1235822, encodeId=c65c123582270, content=偏重的研究方向：胃肠 经验分享：稿费多少钱啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193c8146336, createdName=ms7000000646981835, createdTime=Sun Jul 31 22:09:59 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191094, encodeId=fdbe119109436, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：食管癌;免疫组化 经验分享：请问这个杂志的WOS号多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c665384789, createdName=我恨梅斯Medsci, createdTime=Tue Feb 08 17:41:55 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589105, encodeId=e26a58910511, content=请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5afc5268272, createdName=14818c93m26暂无昵称, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580891, encodeId=9ceb580891c5, content=结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Tue Dec 03 00:00:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576697, encodeId=31975e669707, content=投了137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , beContent=137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575337, encodeId=8a9a5e533738, content=你投了？ ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表: 没有人投这个杂志吗？一点信息都没有, beContent=ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6aca5170385, createdName=146d61a5m67暂无昵称, createdTime=Mon Aug 26 00:00:00 CST 2019, time=2019-08-26, status=1, ipAttribution=)]

2023-06-02 ms6000000805711537 来自四川省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;感染
经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快

43 0

[GetPortalCommentsPageByObjectIdResponse(id=2186676, encodeId=001a21866e6c9, content=有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884f5530521, createdName=ms2000001910337374, createdTime=Fri Feb 09 12:33:15 CST 2024, time=2024-02-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140483, encodeId=e6f4214048336, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;感染 经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a88208497, createdName=ms6000000805711537, createdTime=Fri Jun 02 15:03:18 CST 2023, time=2023-06-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2106507, encodeId=4183210650e75, content=有没有投过的老师分享一下经验呀，初审需要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b35703719, createdName=ms5000000599592392, createdTime=Sat Dec 17 21:00:16 CST 2022, time=2022-12-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1235822, encodeId=c65c123582270, content=偏重的研究方向：胃肠 经验分享：稿费多少钱啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193c8146336, createdName=ms7000000646981835, createdTime=Sun Jul 31 22:09:59 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191094, encodeId=fdbe119109436, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：食管癌;免疫组化 经验分享：请问这个杂志的WOS号多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c665384789, createdName=我恨梅斯Medsci, createdTime=Tue Feb 08 17:41:55 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589105, encodeId=e26a58910511, content=请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5afc5268272, createdName=14818c93m26暂无昵称, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580891, encodeId=9ceb580891c5, content=结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Tue Dec 03 00:00:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576697, encodeId=31975e669707, content=投了137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , beContent=137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575337, encodeId=8a9a5e533738, content=你投了？ ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表: 没有人投这个杂志吗？一点信息都没有, beContent=ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6aca5170385, createdName=146d61a5m67暂无昵称, createdTime=Mon Aug 26 00:00:00 CST 2019, time=2019-08-26, status=1, ipAttribution=)]

2022-12-17 ms5000000599592392 来自甘肃省

有没有投过的老师分享一下经验呀，初审需要多久呢

37 0

[GetPortalCommentsPageByObjectIdResponse(id=2186676, encodeId=001a21866e6c9, content=有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884f5530521, createdName=ms2000001910337374, createdTime=Fri Feb 09 12:33:15 CST 2024, time=2024-02-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140483, encodeId=e6f4214048336, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;感染 经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a88208497, createdName=ms6000000805711537, createdTime=Fri Jun 02 15:03:18 CST 2023, time=2023-06-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2106507, encodeId=4183210650e75, content=有没有投过的老师分享一下经验呀，初审需要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b35703719, createdName=ms5000000599592392, createdTime=Sat Dec 17 21:00:16 CST 2022, time=2022-12-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1235822, encodeId=c65c123582270, content=偏重的研究方向：胃肠 经验分享：稿费多少钱啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193c8146336, createdName=ms7000000646981835, createdTime=Sun Jul 31 22:09:59 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191094, encodeId=fdbe119109436, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：食管癌;免疫组化 经验分享：请问这个杂志的WOS号多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c665384789, createdName=我恨梅斯Medsci, createdTime=Tue Feb 08 17:41:55 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589105, encodeId=e26a58910511, content=请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5afc5268272, createdName=14818c93m26暂无昵称, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580891, encodeId=9ceb580891c5, content=结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Tue Dec 03 00:00:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576697, encodeId=31975e669707, content=投了137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , beContent=137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575337, encodeId=8a9a5e533738, content=你投了？ ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表: 没有人投这个杂志吗？一点信息都没有, beContent=ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6aca5170385, createdName=146d61a5m67暂无昵称, createdTime=Mon Aug 26 00:00:00 CST 2019, time=2019-08-26, status=1, ipAttribution=)]

2022-07-31 ms7000000646981835

偏重的研究方向：胃肠
经验分享：稿费多少钱啊

49 0

[GetPortalCommentsPageByObjectIdResponse(id=2186676, encodeId=001a21866e6c9, content=有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884f5530521, createdName=ms2000001910337374, createdTime=Fri Feb 09 12:33:15 CST 2024, time=2024-02-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140483, encodeId=e6f4214048336, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;感染 经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a88208497, createdName=ms6000000805711537, createdTime=Fri Jun 02 15:03:18 CST 2023, time=2023-06-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2106507, encodeId=4183210650e75, content=有没有投过的老师分享一下经验呀，初审需要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b35703719, createdName=ms5000000599592392, createdTime=Sat Dec 17 21:00:16 CST 2022, time=2022-12-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1235822, encodeId=c65c123582270, content=偏重的研究方向：胃肠 经验分享：稿费多少钱啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193c8146336, createdName=ms7000000646981835, createdTime=Sun Jul 31 22:09:59 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191094, encodeId=fdbe119109436, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：食管癌;免疫组化 经验分享：请问这个杂志的WOS号多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c665384789, createdName=我恨梅斯Medsci, createdTime=Tue Feb 08 17:41:55 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589105, encodeId=e26a58910511, content=请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5afc5268272, createdName=14818c93m26暂无昵称, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580891, encodeId=9ceb580891c5, content=结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Tue Dec 03 00:00:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576697, encodeId=31975e669707, content=投了137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , beContent=137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575337, encodeId=8a9a5e533738, content=你投了？ ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表: 没有人投这个杂志吗？一点信息都没有, beContent=ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6aca5170385, createdName=146d61a5m67暂无昵称, createdTime=Mon Aug 26 00:00:00 CST 2019, time=2019-08-26, status=1, ipAttribution=)]

2022-02-08 我恨梅斯Medsci

审稿速度:3.0 | 投稿命中率:95.0
偏重的研究方向：食管癌;免疫组化
经验分享：请问这个杂志的WOS号多少

46 0

[GetPortalCommentsPageByObjectIdResponse(id=2186676, encodeId=001a21866e6c9, content=有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884f5530521, createdName=ms2000001910337374, createdTime=Fri Feb 09 12:33:15 CST 2024, time=2024-02-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140483, encodeId=e6f4214048336, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;感染 经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a88208497, createdName=ms6000000805711537, createdTime=Fri Jun 02 15:03:18 CST 2023, time=2023-06-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2106507, encodeId=4183210650e75, content=有没有投过的老师分享一下经验呀，初审需要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b35703719, createdName=ms5000000599592392, createdTime=Sat Dec 17 21:00:16 CST 2022, time=2022-12-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1235822, encodeId=c65c123582270, content=偏重的研究方向：胃肠 经验分享：稿费多少钱啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193c8146336, createdName=ms7000000646981835, createdTime=Sun Jul 31 22:09:59 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191094, encodeId=fdbe119109436, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：食管癌;免疫组化 经验分享：请问这个杂志的WOS号多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c665384789, createdName=我恨梅斯Medsci, createdTime=Tue Feb 08 17:41:55 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589105, encodeId=e26a58910511, content=请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5afc5268272, createdName=14818c93m26暂无昵称, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580891, encodeId=9ceb580891c5, content=结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Tue Dec 03 00:00:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576697, encodeId=31975e669707, content=投了137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , beContent=137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575337, encodeId=8a9a5e533738, content=你投了？ ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表: 没有人投这个杂志吗？一点信息都没有, beContent=ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6aca5170385, createdName=146d61a5m67暂无昵称, createdTime=Mon Aug 26 00:00:00 CST 2019, time=2019-08-26, status=1, ipAttribution=)]

2020-04-17 14818c93m26暂无昵称

请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表:
投了

136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了

86 0

[GetPortalCommentsPageByObjectIdResponse(id=2186676, encodeId=001a21866e6c9, content=有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884f5530521, createdName=ms2000001910337374, createdTime=Fri Feb 09 12:33:15 CST 2024, time=2024-02-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140483, encodeId=e6f4214048336, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;感染 经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a88208497, createdName=ms6000000805711537, createdTime=Fri Jun 02 15:03:18 CST 2023, time=2023-06-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2106507, encodeId=4183210650e75, content=有没有投过的老师分享一下经验呀，初审需要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b35703719, createdName=ms5000000599592392, createdTime=Sat Dec 17 21:00:16 CST 2022, time=2022-12-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1235822, encodeId=c65c123582270, content=偏重的研究方向：胃肠 经验分享：稿费多少钱啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193c8146336, createdName=ms7000000646981835, createdTime=Sun Jul 31 22:09:59 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191094, encodeId=fdbe119109436, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：食管癌;免疫组化 经验分享：请问这个杂志的WOS号多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c665384789, createdName=我恨梅斯Medsci, createdTime=Tue Feb 08 17:41:55 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589105, encodeId=e26a58910511, content=请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5afc5268272, createdName=14818c93m26暂无昵称, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580891, encodeId=9ceb580891c5, content=结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Tue Dec 03 00:00:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576697, encodeId=31975e669707, content=投了137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , beContent=137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575337, encodeId=8a9a5e533738, content=你投了？ ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表: 没有人投这个杂志吗？一点信息都没有, beContent=ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6aca5170385, createdName=146d61a5m67暂无昵称, createdTime=Mon Aug 26 00:00:00 CST 2019, time=2019-08-26, status=1, ipAttribution=)]

2019-12-03 1781f75bccm

结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表:
投了

136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了

99 0

[GetPortalCommentsPageByObjectIdResponse(id=2186676, encodeId=001a21866e6c9, content=有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884f5530521, createdName=ms2000001910337374, createdTime=Fri Feb 09 12:33:15 CST 2024, time=2024-02-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140483, encodeId=e6f4214048336, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;感染 经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a88208497, createdName=ms6000000805711537, createdTime=Fri Jun 02 15:03:18 CST 2023, time=2023-06-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2106507, encodeId=4183210650e75, content=有没有投过的老师分享一下经验呀，初审需要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b35703719, createdName=ms5000000599592392, createdTime=Sat Dec 17 21:00:16 CST 2022, time=2022-12-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1235822, encodeId=c65c123582270, content=偏重的研究方向：胃肠 经验分享：稿费多少钱啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193c8146336, createdName=ms7000000646981835, createdTime=Sun Jul 31 22:09:59 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191094, encodeId=fdbe119109436, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：食管癌;免疫组化 经验分享：请问这个杂志的WOS号多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c665384789, createdName=我恨梅斯Medsci, createdTime=Tue Feb 08 17:41:55 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589105, encodeId=e26a58910511, content=请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5afc5268272, createdName=14818c93m26暂无昵称, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580891, encodeId=9ceb580891c5, content=结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Tue Dec 03 00:00:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576697, encodeId=31975e669707, content=投了137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , beContent=137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575337, encodeId=8a9a5e533738, content=你投了？ ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表: 没有人投这个杂志吗？一点信息都没有, beContent=ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6aca5170385, createdName=146d61a5m67暂无昵称, createdTime=Mon Aug 26 00:00:00 CST 2019, time=2019-08-26, status=1, ipAttribution=)]

2019-09-21 120a6ac7m01(暂无昵称)

投了137****6367暂无昵称 2019-08-26 00:00:00 发表:
你投了？

137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？

79 0

[GetPortalCommentsPageByObjectIdResponse(id=2186676, encodeId=001a21866e6c9, content=有一个审稿人给了一个b 一个c 没提什么实质意见，剩下的审稿人都没有回复，直接给我拒了。建议我转投另一个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=884f5530521, createdName=ms2000001910337374, createdTime=Fri Feb 09 12:33:15 CST 2024, time=2024-02-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2140483, encodeId=e6f4214048336, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;感染 经验分享：本次2个审稿人，有个审稿人效率极其高，但是身高不认真，提了一堆问题都是原文中已经写了的。返修邮件我说明了情况，这个审稿人也没有生气，这点倒是挺好。整体来说效率很快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45a88208497, createdName=ms6000000805711537, createdTime=Fri Jun 02 15:03:18 CST 2023, time=2023-06-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2106507, encodeId=4183210650e75, content=有没有投过的老师分享一下经验呀，初审需要多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39b35703719, createdName=ms5000000599592392, createdTime=Sat Dec 17 21:00:16 CST 2022, time=2022-12-17, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1235822, encodeId=c65c123582270, content=偏重的研究方向：胃肠 经验分享：稿费多少钱啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193c8146336, createdName=ms7000000646981835, createdTime=Sun Jul 31 22:09:59 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191094, encodeId=fdbe119109436, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：食管癌;免疫组化 经验分享：请问这个杂志的WOS号多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c665384789, createdName=我恨梅斯Medsci, createdTime=Tue Feb 08 17:41:55 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589105, encodeId=e26a58910511, content=请问现在有结果吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5afc5268272, createdName=14818c93m26暂无昵称, createdTime=Fri Apr 17 00:00:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580891, encodeId=9ceb580891c5, content=结果咋样？审稿快吗？136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, beContent=136bxNT2201(暂无昵称) 2019-09-21 00:00:00 发表: 投了, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a32e2105143, createdName=1781f75bccm, createdTime=Tue Dec 03 00:00:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576697, encodeId=31975e669707, content=投了137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , beContent=137****6367暂无昵称 2019-08-26 00:00:00 发表: 你投了？ , objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=575337, encodeId=8a9a5e533738, content=你投了？ ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表: 没有人投这个杂志吗？一点信息都没有, beContent=ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6aca5170385, createdName=146d61a5m67暂无昵称, createdTime=Mon Aug 26 00:00:00 CST 2019, time=2019-08-26, status=1, ipAttribution=)]

2019-08-26 146d61a5m67暂无昵称

你投了？ ysynl 2019-01-25 发表::
没有人投这个杂志吗？一点信息都没有ysynl 2019-01-25 00:00:00 发表:
没有人投这个杂志吗？一点信息都没有

ysynl 2019-01-25 发表:: 没有人投这个杂志吗？一点信息都没有

101 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务